Triple helix formation in oligonucleotide therapy
CA 2071536 C · Owner: Toole, John · Inventors: Toole, John; Froehler, Brian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Oligonucleotides having tandem sequences of inverted polarity i.e. oligonucleotides comprising regions of the formula: 3'-----5'--C--5'-----3' or 5'-----3'--C--3'-----5' wherein -C- symbolizes any , method of coupling the nucleotide sequence of opposite polarity, are useful for forming an extended triple helix with a doublehelical nucleotide duplex. Single or mixed motif oligomers may be used. The inverted polarity also stabilizes the single-strand oligonucleotides to exonuclease degradation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 23, 1990 and granted April 17, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 23, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 23, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.